Health • Science

Can ER-100 Restore Lost Sight? Inside the First Human Study

A human eye with a hazel iris and natural eyelashes in soft daylight
Share this feature and help others explore their world!

Two of the first three glaucoma participants had better visual-field scores at eight weeks. Here’s what the ER-100 results tell us about the prospect of restoring sight.

Share this feature and help others explore their world!

On a visual-field test, a person looks straight ahead and presses a button each time a small light appears. The resulting map shows where the eye can detect light and where its sensitivity has fallen. In October 2026, the developer of an experimental gene therapy called ER-100 reported that two of its first three participants with open-angle glaucoma performed better on parts of that map eight weeks after treatment. For a disease in which doctors generally focus on preserving the sight a patient still has, the possibility of recovering some lost visual function deserves attention. The odds of reversing blindness remain unknown.

What happened in the first eight weeks?

Life Biosciences announced the interim results on October 8 at Eyecelerator, alongside the American Academy of Ophthalmology’s annual meeting. All three participants received the initial dose level. In each of the two people with a reported improvement, at least 28 percent of the locations tested showed a sensitivity gain greater than four decibels at day 56. That figure describes a share of points on a test map. It gives no percentage for how much vision either participant regained, and the announcement did not establish whether either person could read, recognize faces, or move around more easily.

The company reported no serious adverse events or side effects that limited dosing in this first group through day 56. An independent safety monitoring board recommended moving to the next dose level. That recommendation allows the researchers to ask more about safety and whether a different dose changes the response. Three people followed for eight weeks offer limited information about uncommon side effects, problems that surface later, or the safety of a higher dose. Life Biosciences’ October 8 interim report

Illustration of a person looking into a visual-field testing instrument
In a visual-field test, patients respond to small lights that appear at different locations.

What ER-100 is trying to repair

Retinal ganglion cells collect signals from other cells in the retina. Their long fibers make up the optic nerve, which carries visual information to the brain. When those cells are damaged, parts of the visual field can fade or disappear. ER-100 is designed to change how surviving retinal ganglion cells use some of their genes, with the aim of recovering function. This strategy is called partial epigenetic reprogramming. The trial uses an injection into one eye and a temporary course of an oral medicine to activate the treatment. Researchers are watching both the response in the eye and how well people tolerate the intervention.

The scientific precedent came from a 2020 paper in Nature by Yuancheng Lu and colleagues, including Harvard researcher David Sinclair. The team reported improved visual function in a mouse model of glaucoma and in older mice. In separate experiments involving optic nerve injury, they also reported regrowth of some nerve fibers. That earlier work gave researchers a reason to test the approach in people. The human study still has to answer how much function patients can recover, which patients stand to benefit, and how long an improvement might last. The original study in Nature

Two diseases, two different questions

The registered study includes open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION. Open-angle glaucoma typically damages the optic nerve gradually. NAION usually presents as sudden vision loss when blood supply to the front of the optic nerve is disrupted. Both can leave lasting gaps in the visual field, but the course of injury is different. The October observations involved people with open-angle glaucoma. A benefit in NAION would need evidence from its own participants, including a way to account for changes that can occur after the initial injury.

The trial lists eligibility from ages 40 through 85 and excludes people in the glaucoma group who received their diagnosis before age 40. Other conditions affecting vision can also make a person ineligible. Those criteria matter when interpreting the early results. Someone whose vision loss comes from a different form of glaucoma, a retinal condition, or several problems at once may have a different outlook. The study plans follow-up through year five, giving researchers time to track safety well beyond the first eight weeks. ClinicalTrials.gov study record

What are the odds of reversing blindness?

There is no defensible percentage for ER-100 today. Two favorable test results in three participants describe what the sponsor observed in a small group. They cannot tell us how often a future patient would improve, how much improvement to expect, or whether someone with profound vision loss could regain useful sight. The magnitude of the result also has to be interpreted in the context of an open-label study, where participants and investigators know the treatment was given. The first report offers no randomized comparison from which to estimate how much of the change ER-100 itself caused.

Visual-field exams can vary from one visit to another. Patients can get more comfortable with the test, tire during it, or have trouble keeping their gaze fixed. Researchers will want to see whether the same locations improve across multiple visits and whether changes are more common in treated participants than in a comparison group. Where an improvement occurs matters, too. A repeatable gain near the center of vision may have different consequences for reading than a gain near the edge of the field. A clinical result is easier to interpret when investigators can connect it to what people can see and do. American Academy of Ophthalmology glaucoma guidance

The cause and severity of blindness also shape the outlook. An eye with surviving nerve cells that have lost some function presents one challenge. An eye that has lost much of the nerve tissue needed to carry signals to the brain presents another. The human data released so far give no basis for estimating recovery in an eye with little or no remaining sight. And blindness can originate in the cornea, the light-sensitive cells of the retina, or the brain. A treatment aimed at retinal ganglion cells addresses only part of that spectrum.

What would change the outlook?

The next milestone is a larger set of safety observations and visual-field results that hold up across visits. A later controlled trial could answer the practical questions patients care about. How many people gain enough vision to notice a difference? Which areas of the field improve? Does any benefit persist after activation ends? Does the outlook differ for recent and longstanding damage? Greater clarity about who was treated, including how much vision they had at the start, would make any eventual estimate more meaningful.

Researchers will also need to distinguish recovery from preservation. A treated eye that loses sensitivity more slowly could count as a success in a progressive disease, even if the patient never regains the ability to see in a damaged area. A recovery claim sets a different bar. It requires repeatable improvement over the person’s starting point that exceeds what researchers observe in a suitable comparison group.

Even a limited, durable recovery could matter. Seeing an obstacle sooner or picking up more of a face in conversation may change a person’s daily life without restoring a full visual field. Such benefits would need to be measured in people who receive the therapy. For now, the October results justify pursuing that question, while standard glaucoma treatment remains the established way to protect remaining vision. The result worth watching for is a gain people can use in daily life, documented over time and reproduced in a larger study.

Leave a Reply